title: Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.
abstract: The potential value of glial cell line-derived neurotrophic factor (GDNF) in treating Parkinson's disease (PD) remains controversial. In order to evaluate the therapeutic effect of GDNF-engineered bone marrow stromal cells (BMSCs) in parkinsonian rat model, GDNF-BMSCs and LacZ-BMSCs were transplanted into striatum and followed by Lactacystin lesioning at median forebrain bundles 1 week later. We observed that the intrastriatal transplantation of GDNF-BMSCs could significantly rescue the dopaminergic neurons from lactacystin-induced neurotoxicity with regard to behavioral recovery, tyrosine hydroxylase level in nigra and striatum, and striatal dopamine level. We interpret the outcomes that intrastriatal transplantation of GDNF-BMSCs might be beneficial in the treatment of PD.
authors.affiliation: Department of Neurology, Huashan Hospital Affiliated to Fudan University, 12 Wulumuqi Middle Road, 200040, Shanghai, People's Republic of China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Wu
authors.forename: Wenbo
authors.initials: W
authors.lastname: Yu
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Yaru
authors.initials: Y
authors.lastname: Su
authors.forename: Zhengtong
authors.initials: Z
authors.lastname: Ding
authors.forename: Huimin
authors.initials: H
authors.lastname: Ren
authors.forename: Yuping
authors.initials: Y
authors.lastname: Jiang
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
mesh_terms: D000111:Acetylcysteine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000633:toxicity; D000818:Animals; D000963:Antimetabolites; D001058:Apomorphine; D001522:Behavior, Animal / Q000187:drug effects; D015153:Blotting, Western; D016026:Bone Marrow Transplantation / Q000502:physiology*; D001973:Bromodeoxyuridine; D015853:Cysteine Proteinase Inhibitors / Q000633:toxicity*; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000235:genetics / Q000502:physiology*; D007150:Immunohistochemistry; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000517:prevention & control* / Q000523:psychology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013239:Stereotyped Behavior / Q000187:drug effects; D023822:Tissue Engineering; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D000963:Antimetabolites; D015853:Cysteine Proteinase Inhibitors; D018491:Dopamine Agonists; D051100:Glial Cell Line-Derived Neurotrophic Factor; C067713:lactacystin; D014446:Tyrosine 3-Monooxygenase; D001973:Bromodeoxyuridine; D001058:Apomorphine; D004298:Dopamine; D000111:Acetylcysteine